Why Guardant Health Stock Surged Today
Shares of Guardant Health (NASDAQ: GH) rocketed 28% higher on Thursday after the precision oncology company reported outstanding growth metrics across its key product lines.
Image source: Getty Images.
Guardant's third-quarter revenue soared by 39% year over year to $265.2 million. The gains were broad based. Revenue in the healthcare company's biopharma division jumped 18% to $54.7 million. Sales in its oncology segment leaped 31% to $184.4 million, driven by a roughly 40% increase in oncology tests to 74,000. And revenue in Guardant's promising screening business grew 24-fold to $24.1 million, as Shield screening tests rose to 24,000.
Source Fool.com
